Nuvectis Pharma is a clinical-stage biotechnology company focused on developing novel immunotherapies for patients with solid tumors. The company’s proprietary T-cell activation and expansion platform is designed to enhance the body’s own immune response by targeting tumor-infiltrating lymphocytes. Nuvectis aims to deliver next-generation treatments that address the limitations of existing cancer therapies and provide durable responses in patients with high unmet medical needs.
The company’s lead programs leverage its core technology to identify and expand tumor-specific T cells from patient samples. These expanded cells are engineered to improve persistence, trafficking and cytotoxic activity before being reintroduced into the patient. In early clinical studies, Nuvectis has initiated trials in indications such as melanoma, head and neck carcinoma, and non-small cell lung cancer. Preclinical data suggest that the platform may be adaptable to a range of solid malignancies, with additional programs in development targeting other tumor types.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Nuvectis operates a research and development facility in the Boston area and collaborates with leading academic institutions. The company was formed by a team of entrepreneurs and scientists with deep expertise in cell therapy, immunology and translational oncology. Since inception, it has secured partnerships to advance its pipeline and has grown its laboratory footprint to support clinical manufacturing and scale-up activities.
Nuvectis is led by a management team with extensive experience in biotech and pharmaceuticals, including veterans of large global drug developers and successful cell therapy startups. The board of directors includes oncology researchers and industry executives who guide corporate strategy and oversight. As it advances its clinical programs, Nuvectis remains committed to expanding access to its therapies through strategic collaborations and continued investment in its cell-therapy platform.
AI Generated. May Contain Errors.
